The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China

References

• Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transplant 2012;18:1277–1289
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transplant 2011;17:S1–S9
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Lunz 3rd JG, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009;22:120–141
   PubMed Web of Science ®Google Scholar
• Ashton-Chess J, Giral M, Brouard S, Soulillou JP. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 2007;84:1215–1219
   PubMed Web of Science ®Google Scholar
• Benitez C, Londono MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013;58:1824–1835
   PubMed Web of Science ®Google Scholar
• Levitsky J. Immunosuppression withdrawal following liver transplantation: the older, the wiser… but maybe too late. Hepatology 2013;58:1529–1532
   PubMed Web of Science ®Google Scholar
• Londono MC, Rimola A, O'Grady J, Sanchez-Fueyo A. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol 2013;59:872–879
   PubMed Web of Science ®Google Scholar
• Detry O, de Roover A, Delwaide J, et al. The use of mycophenolate mofetil in liver transplant recipients. Expert Opin Pharmacother 2003;4:1949–1957
   PubMed Web of Science ®Google Scholar
• Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006;82:102–107
   PubMed Web of Science ®Google Scholar
• Nure E, Magalini SC, Frongillo F, et al. Enteric-coated mycophenolate sodium: one-way conversion from mycophenolate mofetil and de novo use in stable liver transplant recipients. Transplant Proc 2009;41:1290–1292
   PubMed Web of Science ®Google Scholar
• Cantisani GP, Zanotelli ML, Gleisner AL, et al. Enteric-coated mycophenolate sodium experience in liver transplant patients. Transplant Proc 2006;38:932–933
   PubMed Web of Science ®Google Scholar
• Lopez-Solis R, DeVera M, Steel J, et al. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transplant 2014;28:783–788
   PubMed Web of Science ®Google Scholar
• Toledo AH, Hendrix L, Buchholz V, et al. Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients. Clin Transplant 2012;26:156–163
   PubMed Web of Science ®Google Scholar
• Schlitt HJ, Barkmann A, Böker KHW, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001;357:587–591
   PubMed Web of Science ®Google Scholar
• Herrero JI, Quiroga J, Sangro B, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transplant Surg 1999;5:414–420
   PubMedGoogle Scholar
• Reyes H, Hernandez AM, Valverde S, et al. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Pediatr Transplant 2010;14:746–752
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Capone D, Gallo R, et al. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol 2009;23:617–624
   PubMed Web of Science ®Google Scholar
• Li P, Shuker N, Hesselink DA, et al. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Transplant Int 2014;27:994–1004
   PubMed Web of Science ®Google Scholar
• Perry TW, Christians U, Trotter JF, Bendrick-Peart J. Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clin Transplant 2007;21:413–416
   PubMed Web of Science ®Google Scholar
• Graefe EU, Wittig J, Mueller S, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001;41:492–499
   PubMed Web of Science ®Google Scholar
• van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:145–154
   PubMed Web of Science ®Google Scholar
• Guillet BA, Simon NS, Purgus R, et al. Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. Ther Drug Monit 2010;32:427–432
   PubMed Web of Science ®Google Scholar
• Kaplan B, Gaston RS, Meier-Kriesche HU, et al. Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Ther Drug Monit 2010;32:224–227
   PubMed Web of Science ®Google Scholar
• Chen H, Chen B. Clinical mycophenolic acid monitoring in liver transplant recipients. World J Gastroenterol 2014;20:10715–10728
   PubMed Web of Science ®Google Scholar
• Fu L, Huang Z, Song T, et al. Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single-center cohort study in Chinese living-related kidney transplantation. Transpl Infect Dis 2014;16:760–766
   PubMed Web of Science ®Google Scholar
• Capone D, Tarantino G, Kadilli I, et al. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric coated mycophenolate sodium (EC-MPS) and cyclosporine. Nephrol Dial Transplant 2011;26:3019–3025
   PubMed Web of Science ®Google Scholar
• Arinsoy T, Uslu A, Mir S, et al. Evaluation of efficacy and safety of mycophenolate sodium in patients with de novo and maintenance renal transplantation: results of a multicenter, prospective, observational study. Transplant Proc 2011;43:826–832
   PubMed Web of Science ®Google Scholar
• Heller T, Geide A, Bonitz U, et al. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. Transplantation 2008;85:739–747
   PubMed Web of Science ®Google Scholar
• Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008;85:1120–1124
   PubMed Web of Science ®Google Scholar
• Burra P, De Martin E, Gitto S, Villa E. Influence of age and gender before and after liver transplantation. Liver Transplant 2013;19:122–134
   PubMed Web of Science ®Google Scholar
• Zheng Z, Lin B, Zhang J, et al. Absolute lymphocyte count recovery at 1 month after transplantation predicts favorable outcomes of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2014;30:706–711
   Web of Science ®Google Scholar